Free Trial

Kyverna Therapeutics (KYTX) Competitors

Kyverna Therapeutics logo
$3.85 -0.48 (-11.09%)
Closing price 07/29/2025 04:00 PM Eastern
Extended Trading
$3.88 +0.03 (+0.91%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KYTX vs. MNMD, ZVRA, DNTH, DAWN, ATAI, AUTL, XNCR, ABVX, TLRY, and MRVI

Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Mind Medicine (MindMed) (MNMD), Zevra Therapeutics (ZVRA), Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), Autolus Therapeutics (AUTL), Xencor (XNCR), Abivax (ABVX), Tilray Brands (TLRY), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

Kyverna Therapeutics vs. Its Competitors

Kyverna Therapeutics (NASDAQ:KYTX) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mind Medicine (MindMed)'s return on equity of -40.33% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -51.66% -45.92%
Mind Medicine (MindMed) N/A -40.33%-32.13%

Kyverna Therapeutics presently has a consensus price target of $18.50, suggesting a potential upside of 380.52%. Mind Medicine (MindMed) has a consensus price target of $24.00, suggesting a potential upside of 162.58%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Mind Medicine (MindMed).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Mind Medicine (MindMed)
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22

In the previous week, Mind Medicine (MindMed) had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 6 mentions for Mind Medicine (MindMed) and 3 mentions for Kyverna Therapeutics. Mind Medicine (MindMed)'s average media sentiment score of 0.99 beat Kyverna Therapeutics' score of 0.88 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kyverna Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mind Medicine (MindMed)
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kyverna Therapeutics has a beta of 2.95, meaning that its share price is 195% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500.

Mind Medicine (MindMed) has lower revenue, but higher earnings than Kyverna Therapeutics. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna Therapeutics$7.03M23.67-$127.48M-$3.38-1.14
Mind Medicine (MindMed)N/AN/A-$108.68M-$1.29-7.09

Summary

Mind Medicine (MindMed) beats Kyverna Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KYTX vs. The Competition

MetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$187.14M$3.02B$5.70B$9.55B
Dividend YieldN/A2.39%4.71%4.03%
P/E Ratio-1.1421.1428.2019.95
Price / Sales23.67206.95390.5767.75
Price / CashN/A42.5736.3258.72
Price / Book0.628.138.275.77
Net Income-$127.48M-$55.06M$3.25B$259.21M
7 Day Performance-11.09%-3.70%-2.00%-2.40%
1 Month Performance25.41%14.45%8.68%9.41%
1 Year Performance-56.00%4.20%34.66%16.67%

Kyverna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KYTX
Kyverna Therapeutics
2.1663 of 5 stars
$3.85
-11.1%
$18.50
+380.5%
-59.3%$187.14M$7.03M-1.1496News Coverage
MNMD
Mind Medicine (MindMed)
2.1718 of 5 stars
$9.95
+12.0%
$25.50
+156.3%
+0.4%$670.91MN/A-7.7140High Trading Volume
ZVRA
Zevra Therapeutics
2.8976 of 5 stars
$11.73
-2.8%
$23.71
+102.2%
+85.1%$659.98M$23.61M-6.1720Analyst Revision
DNTH
Dianthus Therapeutics
1.273 of 5 stars
$20.74
+1.7%
$53.00
+155.5%
-25.9%$656.06M$6.24M-7.2080Upcoming Earnings
DAWN
Day One Biopharmaceuticals
2.9265 of 5 stars
$6.40
flat
$29.00
+353.1%
-54.5%$648.72M$131.16M-9.0160Positive News
Upcoming Earnings
ATAI
atai Life Sciences
3.742 of 5 stars
$3.53
+9.3%
$9.00
+155.0%
+109.5%$647.09M$310K-3.8880Analyst Forecast
Gap Up
High Trading Volume
AUTL
Autolus Therapeutics
2.4451 of 5 stars
$2.43
+0.8%
$9.32
+283.5%
-47.7%$641.40M$10.12M-2.76330Gap Up
XNCR
Xencor
4.4327 of 5 stars
$9.10
+1.4%
$28.00
+207.7%
-58.0%$638.40M$110.49M-2.97280Upcoming Earnings
ABVX
Abivax
3.2345 of 5 stars
$10.14
+1.9%
$31.00
+205.7%
+491.0%$631.55MN/A0.0061Analyst Forecast
High Trading Volume
TLRY
Tilray Brands
1.7456 of 5 stars
$0.67
+8.4%
$1.92
+184.6%
-68.5%$625.34M$788.94M-0.642,650Trending News
Earnings Report
Analyst Forecast
Gap Down
MRVI
Maravai LifeSciences
3.4785 of 5 stars
$2.38
-2.1%
$6.64
+178.9%
-72.8%$618.82M$259.18M-2.09610News Coverage
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:KYTX) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners